查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930164

全球豬疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Porcine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

豬隻疫苗市場成長因素

受豬病發病率上升、豬肉消費量增長以及畜牧衛生管理日益重視等因素的推動，全球豬隻疫苗市場持續穩步擴張。 根據2025年的報告，豬疫苗市場預計在2025年達到12.3億美元，並在2026年成長至13億美元。從長遠來看，預計到2034年，該市場將達到23億美元，這反映了疫苗接種在預防養豬業疾病爆發造成的經濟損失方面發揮的重要作用。

疫苗是動物預防醫學的基石，其設計目的是在不引起疾病的情況下，刺激身體對細菌、病毒和寄生蟲等病原體產生免疫反應。在豬群中，疫苗接種在控制豬繁殖與呼吸綜合症（PRRS）、豬瘟、豬流感和口蹄疫等高傳染性疾病方面發揮著至關重要的作用。隨著養殖集約化程度的提高和牲畜密度的增加，疾病傳播的風險也在增加，因此疫苗接種計劃對於維持豬群生產力和糧食安全至關重要。

市場概覽及主要亮點

預計到2025年，北美將以17.74%的市場佔有率引領豬疫苗市場，這得益於嚴格的動物健康法規、強大的食品安全標準以及預防性獸醫保健的廣泛應用。該地區持續開展針對高影響豬病的研究項目和疫苗開發計劃，進一步鞏固了其領先地位。美國在其中扮演著至關重要的角色，因為豬繁殖與呼吸綜合症（PRRS）造成了巨大的經濟負擔，僅此一項每年就造成約5.6億美元的損失。

亞太地區是成長最快的區域市場，這主要得益於高豬肉產量、不斷提高的生物安全意識以及政府主導的疫苗接種計劃的增加。中國和日本等國家正在強調群體免疫的重要性，以保護其龐大的豬肉供應鏈。 由於豬流感的高發生率（估計有 56.6% 的豬群受到影響）以及該地區對先進基因型特異性疫苗的強有力的監管支持，歐洲佔了相當大的市場佔有率。

市場動態

市場驅動因素

豬群疾病發生率的上升和全球豬肉消費量的成長是市場成長的關鍵驅動因素。全球生產數據顯示，到 2023 年，豬肉產量將達到約 1.2467 億噸，凸顯了健康牲畜滿足蛋白質需求的重要性。人們對人畜共通傳染病傳播的認識不斷提高，進一步促使畜牧生產者投資於常規疫苗接種，以保護動物和人類的健康。

市場限制因子

發展中地區疫苗接種率有限，繼續限制市場成長。獸醫基礎設施不足、意識薄弱和資金限制等因素阻礙了疫苗的普及。 研究表明，發展中國家約 50.0% 的可預防牲畜死亡與傳染病有關，凸顯了疫苗接種覆蓋率的差距。

市場機會

政府支持的疫苗接種計劃提供了巨大的成長機會。政府致力於預防經典豬瘟和豬繁殖與呼吸綜合症 (PRRS) 的各項措施正在擴大疫苗的供應。針對數十萬頭豬的大規模疫苗接種活動正在增強新興市場對豬隻疫苗的需求。

市場挑戰

PRRS 和豬流感等病原體的快速基因突變會造成疫苗不相容的風險，降低疫苗效力，並需要頻繁地重新配製疫苗。 此外，複雜的監管架構和冗長的審批流程會延緩產品上市，為生產商帶來挑戰。

市場趨勢

豬免疫技術的進步，特別是基因型特異性疫苗的研發，是該產業的主要趨勢。這些疫苗利用基因組數據更精準地針對流行病原體株，增強免疫反應並控制疾病。生物技術和疫苗配方方面的創新正在改善豬群健康，並減少與呼吸道疾病相關的經濟損失。

市場區隔分析

依產品分類

滅活疫苗因其卓越的安全性和抑制病毒爆發的有效性而佔市場主導地位。減毒活疫苗也佔了相當大的佔有率，這得益於其誘導長期免疫的能力。 重組疫苗因其靶向免疫反應和成本效益高的生產方式而備受關注。

依給藥途徑

由於其快速活化免疫反應和高效性，腸外給藥途徑佔市場主導地位。口服疫苗因其給藥方便且易於規模化，預計將增長更快，尤其是在大規模疫苗接種計劃中。

依分銷管道

獸醫院憑藉其先進的診斷和治療能力，佔最大的市場佔有率。動物診所和研究機構透過常規疫苗接種服務和持續的疫苗研發，穩步貢獻市場佔有率。

"全球豬疫苗市場（2025）" 報告對2025年、2026年和2034年的市場規模和價值進行了全面分析，涵蓋產品細分、給藥途徑、分銷渠道、區域表現、競爭格局、主要行業趨勢以及新冠疫情的影響。 本報告重點關注疾病流行情況、疫苗接種指南以及塑造豬免疫未來發展的創新趨勢。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區豬病概覽（2025 年）
  • 主要國家及地區監理現況（2025 年）
  • 豬病疫苗接種概覽
  • 主要公司新產品發布
  • 主要產業趨勢：併購、業務合作等
  • 影響COVID-19 對全球豬隻疫苗市場的影響

第五章 全球豬隻疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • 滅活​​疫苗
    • 減毒活疫苗
    • 重組疫苗
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 注射
  • 市場分析、洞察與預測：依銷售管道
    • 獸醫院
    • 獸醫診所
    • 藥局
    • 其他
  • 市場分析、洞察與預測：依地區
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美豬疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲豬疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 其他歐洲國家

第八章 亞太豬疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲豬疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲豬疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南亞非洲
    • 中東和非洲其他地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • Elanco
    • HIPRA
    • Boehringer Ingelheim International GmbH
    • Virbac
    • Merck &Co., Inc.
    • Zoetis Services LLC
    • Ceva
    • NEOGEN CORPORATION
    • Hester Biosciences Limited
Product Code: FBI112834

Growth Factors of porcine vaccines Market

The global porcine vaccines market is witnessing steady expansion, driven by the increasing prevalence of swine diseases, rising pork consumption, and the growing emphasis on livestock health management. According to the 2025 report year, the porcine vaccines market was valued at USD 1.23 billion in 2025 and is projected to grow to USD 1.30 billion in 2026. Over the long-term forecast horizon, the market is expected to reach USD 2.30 billion by 2034, reflecting the essential role of vaccination in preventing economic losses associated with disease outbreaks in pig farming.

Vaccines are a cornerstone of preventive veterinary healthcare, designed to stimulate immune responses against pathogens such as bacteria, viruses, and parasites without causing disease. In pig populations, vaccination plays a critical role in controlling highly contagious conditions such as Porcine Reproductive and Respiratory Syndrome (PRRS), classical swine fever, swine influenza, and foot-and-mouth disease. Increasing farm intensification and dense animal populations have heightened disease transmission risks, making vaccination programs indispensable for maintaining herd productivity and food security.

Market Overview and Key Highlights

In 2025, North America dominated the porcine vaccines market with a 17.74% market share, supported by strict animal health regulations, strong food safety standards, and widespread adoption of preventive veterinary care. The region's leadership is reinforced by continuous research initiatives and vaccine development programs targeting high-impact swine diseases. The U.S. plays a pivotal role due to the high economic burden of PRRS, which alone costs the industry approximately USD 560.0 million annually.

Asia Pacific represents the fastest-growing regional market, fueled by high pork production volumes, rising awareness of biosecurity, and increasing government-led vaccination initiatives. Countries such as China and Japan are emphasizing herd immunity to protect large-scale pork supply chains. Europe holds a significant share due to the high prevalence of swine influenza, affecting an estimated 56.6% of herds, and the region's strong regulatory support for advanced genotype-specific vaccines.

Market Dynamics

Market Drivers

The rising prevalence of swine diseases and increasing global pork consumption are key drivers of market growth. According to global production data, pig meat output reached approximately 124.67 million tons in 2023, underscoring the need for healthy livestock to meet protein demand. Awareness of zoonotic disease transmission has further encouraged farmers to invest in routine vaccination to safeguard animal and human health.

Market Restraints

Limited adoption of immunization in developing regions continues to restrain market growth. Factors such as inadequate veterinary infrastructure, low awareness, and financial constraints hinder vaccine penetration. Studies indicate that nearly 50.0% of preventable livestock deaths in developing countries are linked to infectious diseases, highlighting gaps in vaccination coverage.

Market Opportunities

Government-supported vaccination programs offer significant growth opportunities. Public initiatives focusing on classical swine fever and PRRS prevention are expanding vaccine accessibility. Large-scale immunization campaigns targeting hundreds of thousands of pigs are strengthening demand for porcine vaccines across emerging markets.

Market Challenges

Rapid genetic mutations in pathogens such as PRRS virus and swine influenza create vaccine mismatch risks, reducing efficacy and requiring frequent reformulation. Additionally, complex regulatory frameworks and lengthy approval processes can delay product launches, posing challenges for manufacturers.

Market Trends

Technological advancements in porcine immunization, particularly the development of genotype-specific vaccines, represent a major industry trend. These vaccines leverage genomic data to target prevalent pathogen strains more precisely, improving immune response and disease control. Innovations in biotechnology and vaccine formulation are enhancing herd health outcomes and reducing economic losses linked to respiratory disease complexes.

Segmentation Analysis

By Product

The inactivated vaccines segment held a dominant share due to its strong safety profile and effectiveness in controlling viral outbreaks. Live attenuated vaccines also accounted for a substantial share, supported by their ability to induce long-lasting immunity. Recombinant vaccines are gaining traction due to targeted immune responses and cost-efficient production.

By Route of Administration

The parenteral route leads the market, driven by rapid immune activation and high efficacy. Oral vaccines are expected to grow faster, particularly for mass vaccination programs, due to ease of administration and scalability.

By Distribution Channel

Veterinary hospitals account for the largest share, supported by advanced diagnostic and treatment capabilities. Veterinary clinics and research institutes contribute steadily through routine immunization services and ongoing vaccine development.

Competitive Landscape

The porcine vaccines market is moderately consolidated, with key players including Zoetis Services LLC, Merck & Co., Inc., Elanco, Virbac, and Ceva. These companies focus on expanding product portfolios, strategic acquisitions, and geographic expansion to strengthen market presence.

Report Coverage

The 2025 porcine vaccines market report provides a comprehensive analysis of market size and value for 2025, 2026, and 2034, covering product segmentation, routes of administration, distribution channels, regional performance, competitive landscape, key industry developments, and the impact of COVID-19. The report emphasizes disease prevalence, vaccination guidelines, and innovation trends shaping the future of porcine immunization.

Conclusion

The global porcine vaccines market is expected to maintain steady and sustainable growth throughout the forecast period, supported by the rising prevalence of swine diseases, increasing pork consumption, and growing awareness of preventive animal healthcare. With the market valued at USD 1.23 billion in 2025, projected to reach USD 1.30 billion in 2026, and further expanding to USD 2.30 billion by 2034, the outlook highlights the critical role of vaccination in protecting herd health and minimizing economic losses in pig farming. North America's leadership, holding 17.74% market share in 2025, reflects the impact of stringent animal health regulations and advanced veterinary infrastructure, while Asia Pacific's rapid growth underscores expanding vaccination initiatives and high pork production volumes. Despite challenges such as limited immunization adoption in developing regions, pathogen mutation, and regulatory complexity, continuous technological advancements, genotype-specific vaccines, and strong government-backed vaccination programs are strengthening market fundamentals. Overall, the porcine vaccines market is well-positioned for long-term expansion, driven by innovation, disease prevention priorities, and the global demand for safe and sustainable animal protein.

Segmentation By Product

  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Porcine Diseases by Key Countries, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Overview of Vaccination for Porcine Diseases
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Porcine Vaccines Market

5. Global Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Recombinant
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Veterinary Hospitals
    • 5.3.2. Veterinary Clinics
    • 5.3.3. Pharmacies & Drug Stores
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Recombinant
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Veterinary Hospitals
    • 6.3.2. Veterinary Clinics
    • 6.3.3. Pharmacies & Drug Stores
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Recombinant
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Veterinary Hospitals
    • 7.3.2. Veterinary Clinics
    • 7.3.3. Pharmacies & Drug Stores
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Recombinant
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Veterinary Hospitals
    • 8.3.2. Veterinary Clinics
    • 8.3.3. Pharmacies & Drug Stores
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Recombinant
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Veterinary Hospitals
    • 9.3.2. Veterinary Clinics
    • 9.3.3. Pharmacies & Drug Stores
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Recombinant
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Veterinary Hospitals
    • 10.3.2. Veterinary Clinics
    • 10.3.3. Pharmacies & Drug Stores
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Elanco
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. HIPRA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Boehringer Ingelheim International GmbH
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Virbac
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck & Co., Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Zoetis Services LLC
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Ceva
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. NEOGEN CORPORATION
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Hester Biosciences Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 6: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 18: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Porcine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Porcine Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Porcine Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Porcine Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 7: North America Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 8: North America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Porcine Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Porcine Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 15: Europe Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 16: Europe Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 31: Latin America Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Porcine Vaccines Market Share (%), By Company, 2025